Current research on Mdm2/MdmX primarily focuses on the mechanisms of their interaction with p53, the regulation of this interaction, and the development of Mdm2 and MdmX inhibitors that activate p53’s tumor-suppressing activity [14,15,16]. The gene discussed is TP53; the disease is neoplasm.